Allogene Therapeutics(ALLO) - 2024 Q4 - Annual Results

Exhibit 99.1 Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update SOUTH SAN FRANCISCO, Calif., March 13, 2025 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter and full year ended December 31, 2024. "In 2024, we focused on delivering on our bol ...